BioPorto er et dansk In-vitro diagnostisk (IVD) selskab med hovedkontor i København, Danmark. Selskabet blev grundlagt i 2000. BioPorto har allerede ét produkt på markedet, NGAL-testen, som er til tidlig diagnosticering af akutte nyreskade (AKI). Den er kommercielt tilgængelig i Europa, Canada, Asien og Israel.
NGAL-testen har modtaget banebrydende betegnelser fra FDA for akutte nyreskader til babyer, børn og unge under 18 år for hvilken den i øjeblikket udfører dataanalyser efter afslutningen af indrulning af patienter til dets fase 3-studie, som vil føre til en ansøgning til FDA. Fremtidige planer inkluderer yderligere FDA-indsendelse til voksenindikation såvel som andre markeder.
CEO Peter M. Eriksen confirmed the solid underlying growth in The NGAL-test in CE marked areas of 25%YoY, further the company keeps a tight cost control and holds DKK 66 mio. in cash end 2023.
Mød og stil spørgsmål til BioPorto’s interim CEO Peter M. Eriksen d. 4. april kl. 10.00. Eventet indledes med en præsentation af selskabets regnskab for 2023 og forventninger til 2024. Herefter vil der være mulighed for spørgsmål.
After a slow start to 2024, February and the beginning of March turned out to be a very strong period for Biotech and Life Science stocks as illustrated above. Even more so, if measured since late October 2023. Looking at 2024, the general S&P Biotech index is now up 7.7 percent year-to-date, outperforming MSCI World All Countries which is up 7.0 percent. Nordic focused HCA Little Mermaid index is up 6.0 percent.
BioPorto announces ambitious strategy-plan, but investor concern regarding an upcoming rights issue has put pressure on the stock
BioPorto pre-announced part of their 2023 report last week, which is scheduled to be published in full on April 4th. BioPortro expects revenue of DKK 40 mill. and an EBITDA of -80 mill. in 2024. More importantly, BioPorto also announced its new strategy which is expected to bring BioPorto to plus USD 100 mill. in annual revenue over the next 5 years.
The investment case is driven by the potential for BioPorto to successfully leverage the marketing authorization (FDA approval) for ProNephro AKI for pediatrics, to also be approved for adult use, as well as, for use in other settings and in other geographical areas (Rest of World).